|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
135,340,000 |
Market
Cap: |
548.13(M) |
Last
Volume: |
11,363,101 |
Avg
Vol: |
11,332,083 |
52
Week Range: |
$2.65 - $5.59 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Co.'s primary program, molgramostim nebulizer solution is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor and is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. Molgramostim nebulizer solution is administered once daily by inhalation via a nebulizer, the eFlow® Nebulizer System. The eFlow® Nebulizer System is a reusable electronic inhalation system. Molgramostim was also being investigated in cystic fibrosis (CF) and non-CF patients for the treatment of nontuberculous mycobacterial lung infection, a lung disorder.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
3,339,830 |
4,023,225 |
Total Buy Value |
$0 |
$0 |
$10,019,035 |
$11,106,809 |
Total People Bought |
0 |
0 |
11 |
12 |
Total Buy Transactions |
0 |
0 |
11 |
42 |
Total Shares Sold |
0 |
187,843 |
187,843 |
187,843 |
Total Sell Value |
$0 |
$885,322 |
$885,322 |
$885,322 |
Total People Sold |
0 |
3 |
3 |
3 |
Total Sell Transactions |
0 |
3 |
3 |
3 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Yang Rick |
10% Owner |
|
2023-07-17 |
4 |
B |
$3.00 |
$999,999 |
I/I |
333,333 |
24,471,264 |
1.5 |
19% |
|
Chang Carmen |
10% Owner |
|
2023-07-17 |
4 |
B |
$3.00 |
$999,999 |
I/I |
333,333 |
24,471,264 |
1.5 |
19% |
|
Sandell Scott D |
10% Owner |
|
2023-07-17 |
4 |
B |
$3.00 |
$999,999 |
I/I |
333,333 |
24,471,264 |
1.5 |
19% |
|
Mathers Edward T |
10% Owner |
|
2023-07-17 |
4 |
B |
$3.00 |
$999,999 |
I/I |
333,333 |
24,471,264 |
1.5 |
19% |
|
New Enterprise Associates 17, L.p. |
10% Owner |
|
2023-07-17 |
4 |
B |
$3.00 |
$999,999 |
D/D |
333,333 |
24,471,264 |
2.45 |
19% |
|
Baskett Forest |
10% Owner |
|
2023-07-17 |
4 |
B |
$3.00 |
$999,999 |
I/I |
333,333 |
24,471,264 |
1.5 |
19% |
|
Walker Paul Edward |
10% Owner |
|
2023-07-17 |
4 |
B |
$3.00 |
$999,999 |
I/I |
333,333 |
24,471,264 |
1.5 |
19% |
|
Pratt Raymond Dennis |
Chief Medical Officer |
|
2023-06-26 |
4 |
B |
$2.93 |
$19,045 |
D/D |
6,500 |
160,000 |
2.74 |
38% |
|
Ramsay David A |
Director |
|
2023-05-26 |
4 |
B |
$2.63 |
$97,599 |
D/D |
37,124 |
2,201,142 |
2.39 |
42% |
|
Ramsay David A |
Director |
|
2023-05-25 |
4 |
B |
$2.57 |
$33,130 |
D/D |
12,876 |
2,164,018 |
2.39 |
41% |
|
Ramsay David A |
Director |
|
2023-05-24 |
4 |
B |
$2.56 |
$127,800 |
D/D |
50,000 |
2,151,142 |
2.39 |
39% |
|
Lutz Robert Matthew |
Chief Operating Officer |
|
2023-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
140,000 |
140,000 |
|
- |
|
Ramsay David A |
Director |
|
2022-12-30 |
4 |
B |
$1.55 |
$44,834 |
D/D |
29,000 |
2,101,142 |
2.39 |
25% |
|
Ramsay David A |
Director |
|
2022-12-29 |
4 |
B |
$1.54 |
$10,752 |
D/D |
7,000 |
2,072,142 |
2.39 |
24% |
|
Ramsay David A |
Director |
|
2022-12-28 |
4 |
B |
$1.50 |
$4,923 |
D/D |
3,293 |
2,065,142 |
2.31 |
23% |
|
Ramsay David A |
Director |
|
2022-12-23 |
4 |
B |
$1.44 |
$22,665 |
D/D |
15,707 |
2,061,849 |
2.39 |
35% |
|
Ramsay David A |
Director |
|
2022-12-22 |
4 |
B |
$1.48 |
$61,127 |
D/D |
41,414 |
2,046,142 |
2.39 |
30% |
|
Pratt Raymond Dennis |
Chief Medical Officer |
|
2022-12-22 |
4 |
B |
$1.54 |
$5,402 |
D/D |
3,500 |
153,500 |
2.74 |
30% |
|
Ramsay David A |
Director |
|
2022-12-20 |
4 |
B |
$1.48 |
$5,307 |
D/D |
3,586 |
2,004,728 |
2.39 |
29% |
|
Ramsay David A |
Director |
|
2022-12-20 |
4 |
B |
$1.50 |
$20,759 |
D/D |
13,830 |
2,001,142 |
2.39 |
29% |
|
Ramsay David A |
Director |
|
2022-12-19 |
4 |
B |
$1.49 |
$60,834 |
D/D |
40,719 |
1,987,312 |
2.39 |
30% |
|
Ramsay David A |
Director |
|
2022-12-16 |
4 |
B |
$1.50 |
$512 |
D/D |
341 |
1,946,593 |
2.31 |
24% |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2022-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
325,000 |
1,046,354 |
|
- |
|
Lowrance David L |
CHIEF FINANCIAL OFFICER |
|
2022-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
242,793 |
|
- |
|
Elam Nevan C |
Director |
|
2022-12-13 |
4 |
OE |
$0.65 |
$762 |
D/D |
1,172 |
29,244 |
|
- |
|
179 Records found
|
|
Page 2 of 8 |
|
|